Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:05 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2521–2544 of 9,820 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Advanced Malignancy Clear all

Conditions: Breast Cancer
Interventions: Fulvestrant, GDC-0941, GDC-0941 Matching Placebo, GDC-0980, GDC-0980 Matching Placebo; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 41
States / cities: Birmingham, Alabama • Hayward, California • Oakland, California + 35 more

Conditions: Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
Interventions: Zongertinib, Trastuzumab deruxtecan, Trastuzumab emtansine, Trastuzumab, Capecitabine, mFOLFOX6, zanidatamab, Docetaxel; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 26
States / cities: Cerritos, California • Los Angeles, California • Orange, California + 18 more

Conditions: Advanced Solid Tumors
Interventions: OTP-01; Drug
Lead sponsor: Ottimo Pharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: New Haven, Connecticut • Boston, Massachusetts • Grand Rapids, Michigan + 2 more

Conditions: Advanced Solid Tumors, Breast Cancer Recurrent, Ovarian Cancer, High-grade Serous Ovarian Carcinoma, Triple Negative Breast Cancer, sqNSCLC, Squamous Non-small-cell Lung Cancer
Interventions: ATX-295, ATX-295 and bevacizumab (or biosimilar); Drug
Lead sponsor: Accent Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 11
States / cities: Aurora, Colorado • Sarasota, Florida • Detroit, Michigan + 8 more

Conditions: Hepatocellular Carcinoma
Interventions: Nivolumab, Ipilimumab, Sorafenib, lenvatinib; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 15
States / cities: Tucson, Arizona • Coronado, California • Duarte, California + 12 more

Conditions: Solid Tumor, Lymphoma
Interventions: DZ-002; Drug
Lead sponsor: Da Zen Theranostics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma of the Skin, Sarcoma of the Skin, Basal Cell Cancer of the Skin, Breast Cancer
Interventions: Poly-ICLC; Drug
Lead sponsor: Nina Bhardwaj; Other
Eligibility: 14 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Urothelial Bladder Cancer, Triple-negative Breast Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Tremelimumab monotherapy, MEDI4736 monotherapy, MEDI4736 + tremelimumab combination therapy; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 150 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 3
States / cities: San Francisco, California • Memphis, Tennessee • Houston, Texas

Conditions: Mycosis Fungoides, Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8
Interventions: Pembrolizumab; Biological
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
Interventions: BT5528, Nivolumab; Drug
Lead sponsor: BicycleTx Limited; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Encinitas, California • Orange, California • Denver, Colorado + 9 more

Conditions: Solid Cancers
Interventions: Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 8
States / cities: Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more

Conditions: Locally Advanced Unresectable or Metastatic Melanoma
Interventions: Selinexor, Pembrolizumab; Drug
Lead sponsor: Karyopharm Therapeutics Inc; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 13
States / cities: Los Angeles, California • Pasadena, California • Plantation, Florida + 10 more

Conditions: Brain Tumor
Interventions: MRI; Other
Lead sponsor: St. Joseph's Hospital and Medical Center, Phoenix; Other
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Solid Tumors
Interventions: Dexamethasone, Placebo; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2028
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Interventions: Loncastuximab Tesirine and Durvalumab; Drug
Lead sponsor: ADC Therapeutics S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Birmingham, Alabama • Colorado Springs, Colorado • Gainesville, Florida + 6 more

Conditions: Advanced Gastric Cancer
Interventions: Nivolumab, Ipilimumab, Relatlimab, BMS-986205, Rucaparib; Biological · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 16
States / cities: Phoenix, Arizona • Duarte, California • Aurora, Colorado + 13 more

Conditions: Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
Interventions: Elironrasib, Daraxonrasib; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 534 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 23
States / cities: Duarte, California • Orange, California • Sacramento, California + 17 more

Conditions: Non-Small Cell Lung Cancer (NSCLC)
Interventions: Alectinib, Bevacizumab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pheochromocytoma, Paraganglioma
Interventions: Zanzalintinib; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Non-Small Cell Lung Cancer
Interventions: IMO-2055; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 9
States / cities: Ocoee, Florida • Indianapolis, Indiana • Albany, New York + 6 more

Conditions: Lung Cancer
Interventions: mutant p53 peptide pulsed dendritic cell vaccine, adjuvant therapy; Biological · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2005
U.S. locations: 2
States / cities: Bethesda, Maryland • Nashville, Tennessee

Conditions: Multiple Myeloma
Interventions: Transfusion; Procedure
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: GIST, Metastatic Disease
Interventions: Nilotinib, Nilotinib with Imatinib; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 3
States / cities: St Louis, Missouri • Winston-Salem, North Carolina • Philadelphia, Pennsylvania

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: FKB238 (bevacizumab), Avastin (bevacizumab), Paclitaxel, Carboplatin; Drug
Lead sponsor: Centus Biotherapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 731 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 11
States / cities: Fountain Valley, California • Whittier, California • Jacksonville, Florida + 7 more

Search by objective public record fields.

Study of GDC-0941 or GDC-0980 With Fulvestrant Versus Fulvestrant in Advanced or Metastatic Breast Cancer in Participants Resistant to Aromatase Inhibitor Therapy

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, as Monotherapy and in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

A Pharmacokinetic and Pharmacodynamic Study of DZ-002 in Patients With Advanced Solid Malignancies or Lymphoma

Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)

Study of Tremelimumab in Patients With Advanced Solid Tumors

Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma

Development and Validation of Advanced MRI Methods for Clinical Applications

Dexamethasone for Symptom Burden in Advanced Cancer Patients

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

A Study to Test Combination Treatments in Participants With Advanced Gastric Cancer

Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Zanzalintinib in Unresectable and Progressive MPGGs

Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC

Vaccine Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

UARK 2006-28 Human Cord Blood Transplantation in Advanced Hematological Malignancies

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer